1. Insulin Degludec: A Significant Advancement in Ultralong-Acting Basal Insulin

   • Sanjay Kalra

   Editorial Open access 20 November 2013 Pages: 167 - 173

2. Adherence to Therapies in Patients with Type 2 Diabetes

   • Luis-Emilio García-Pérez
   • María Álvarez
   • Domingo Orozco-Beltrán

   Review Open access 30 August 2013 Pages: 175 - 194

   

3. Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes Mellitus

   • Harold Bays

   Review Open access 19 October 2013 Pages: 195 - 220

   

4. Incretin-Based Therapies: Focus on Effects Beyond Glycemic Control Alone

   • Jaime A. Davidson

   Review Open access 21 September 2013 Pages: 221 - 238

   

5. Management of Type 2 Diabetes Mellitus in Older Patients: Current and Emerging Treatment Options

   • Etie Moghissi

   Review Open access 05 October 2013 Pages: 239 - 256

6. Experience with Vildagliptin in Patients ≥75 Years with Type 2 Diabetes and Moderate or Severe Renal Impairment

   • Anja Schweizer
   • Sylvie Dejager

   Original Research Open access 03 July 2013 Pages: 257 - 267

   

7. Adding Saxagliptin to Metformin Extended Release (XR) or Uptitration of Metformin XR: Efficacy on Daily Glucose Measures

   • Joel M. Neutel
   • Cathy Zhao
   • Chetan S. Karyekar

   Original Research Open access 24 July 2013 Pages: 269 - 283

   

8. Using Exenatide Twice Daily or Insulin in Clinical Practice: Results from CHOICE

   • Chantal Mathieu
   • Claes-Göran Östenson
   • Michael Theodorakis

   Original Research Open access 10 September 2013 Pages: 285 - 308

   

9. Safety and Effectiveness of Switching from a Basal-only to Biphasic Insulin Aspart 30 Insulin Regimen

   • Jihad Haddad
   • Mohsen Khoshniatnikoo
   • Pradana Soewondo

   Original Research Open access 12 July 2013 Pages: 309 - 319

   

10. Vildagliptin is Effective for Glycemic Control in Diabetic Patients Undergoing either Hemodialysis or Peritoneal Dialysis

    • Hiroyuki Ito
    • Mizuo Mifune
    • Tsutomu Sanaka

    Original Research Open access 26 June 2013 Pages: 321 - 329

    

11. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus

    • Tim Heise
    • Leo Seman
    • Klaus Dugi

    Original Research Open access 10 July 2013 Pages: 331 - 345

    

12. Safety and Effectiveness of Biphasic Insulin Aspart 30 in Different Age-Groups: A₁chieve Sub-Analysis

    • Mohammad Ebrahim Khamseh
    • Jihad Haddad
    • Mohammad Imtiaz Hasan

    Original Research Open access 17 July 2013 Pages: 347 - 361

13. Annual Medical Costs of Swedish Patients with Type 2 Diabetes Before and After Insulin Initiation

    • Christin Bexelius
    • Johan Lundberg
    • Hans Hjelm

    Original Research Open access 20 August 2013 Pages: 363 - 374

    

14. Initial Management of Severe Hyperglycemia in Patients with Type 2 Diabetes: an Observational Study

    • William M. King IV
    • Michael T. McDermott
    • Jennifer M. Trujillo

    Original Research Open access 16 August 2013 Pages: 375 - 384

    

15. Experience with Vildagliptin in Type 2 Diabetic Patients Fasting During Ramadan in France: Insights from the VERDI Study

    • Serge Halimi
    • Marc Levy
    • Sylvie Dejager

    Original Research Open access 31 August 2013 Pages: 385 - 398

    

16. Clinical Experience with Insulin Detemir in Patients with Type 2 Diabetes from the Near East Countries

    • Akram Echtay
    • Anat Tsur
    • Bracha Dagan

    Original Research Open access 10 October 2013 Pages: 399 - 408

17. Efficacy of Initial Basal-Supported Oral Therapy with Sitagliptin in Untreated Type 2 Diabetes

    • Keiji Yoshioka

    Original Research Open access 15 October 2013 Pages: 409 - 416

    

18. Incretin Therapy for Type 2 Diabetes in Spain: A Cost-Effectiveness Analysis of Liraglutide Versus Sitagliptin

    • Pedro Mezquita Raya
    • Antonio Pérez
    • William J. Valentine

    Original Research Open access 17 October 2013 Pages: 417 - 430

    

19. Dipeptidyl Peptidase-4 Inhibition in Patients with Type 2 Diabetes Treated with Saxagliptin, Sitagliptin, or Vildagliptin

    • Daniel A. Tatosian
    • Ying Guo
    • Eunkyung A. Kauh

    Original Research Open access 26 October 2013 Pages: 431 - 442

    

20. Physician Preferences for Extra-Glycemic Effects of Type 2 Diabetes Treatments

    • Christine Poulos
    • Juan Marcos González
    • Mark A. Deeg

    Original Research Open access 20 November 2013 Pages: 443 - 459

    

21. Effects of Switching from Insulin Glargine or Detemir to Insulin Degludec in Patients with Type 1 Diabetes Mellitus

    • Yoshiki Kusunoki
    • Tomoyuki Katsuno
    • Mitsuyoshi Namba

    Original Research Open access 27 November 2013 Pages: 461 - 472

    

22. Age-Specific Effectiveness and Safety of Newly Initiated Insulin Therapy in Japanese Patients with Uncontrolled Diabetes

    • Takayoshi Shiga
    • Hirohide Yokokawa
    • Hiroshi Isonuma

    Original Research Open access 10 December 2013 Pages: 473 - 486

    

23. Erratum to: Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies

    • Samuel S. Engel
    • Elizabeth Round
    • Barry J. Goldstein

    Erratum Open access 10 July 2013 Pages: 487 - 487